Company officials said they expect the firm's growth momentum to continue in 2019, with increased penetration both in the US and in European markets.
The firm's diagnostics and genomics group saw a 13 percent year-over-year revenue increase in the first quarter.
The company said that three unnamed insiders who are in control of the company are expected to subscribe for most of the securities for sale.
DOJ alleges that Arriva offered free upgrades of medically unnecessary glucometers to Medicare beneficiaries, and then billed Medicare for the equipment.
The point-of-care test will use the companies' respective technologies and detect two protein biomarkers of inflammation and immune system activity.
The platform enables the assessment of hemoglobin levels at the point of care and quantitatively measures hemoglobin in capillary or venous whole blood.
Quest will provide management expertise, lab equipment, supplies, procurement processes, and reference testing to Houston Medical Center and Perry Hospital.
For the last three months of 2018, Invitae reported $45.4 million in revenues compared to $25.4 million in Q4 2017, beating the consensus Wall Street estimate.
The firm said that the test provides results of HBV status in 15 minutes with high analytical sensitivity, and that testing can be completed while the patient is present.
The company has adopted a reagent rental approach which it believes supported the placement of 133 instruments in the quarter.
As part of the collaboration, Belgium-based Diploid will integrate Genomenon's Mastermind genomic search engine into its Moon diagnostic software.
The firms said that HuaSin obtained exclusive rights to develop a fully automated HPV genotyping assay platform that uses Genomica’s technology.
Under the terms of the agreement, Yourgene will offer its NIPT products on Thermo's NGS instruments in Southeast Asia and pay off its debts to Thermo.
Test volumes, revenues per test and costs per test improved during the quarter, company executives said.
The new center will focus on liquid biopsy technologies for tracking treatment response and for monitoring patients with minimal residual disease.